Verucerfont

Research use only, not for human use.

Verucerfont is an antagonist of corticotropin-releasing factor receptor 1 (CRF1) .

Verucerfont is an antagonist of corticotropin-releasing factor receptor 1 (CRF1) .(In Vivo):Post hoc analysis shows that the prototypic non-peptide CRF1 receptor antagonist NBI30775 (R121919) and Verucerfont are both significantly different from vehicle, CP-316 311, and pexacerfont (P<0.001 for all comparisons collapse across time-points); the latter three treatments in turn do not differ from each other. A differential effect of treatments over time is also shown by a significant treatment×time interaction (F[20,140]=6.4, P<0.001). Accordingly, detailed Post hoc analysis shows that both NBI30775 and Verucerfont inhibit ACTH release throughout the following 6 h of measurement (P<0.001 vs vehicle at each time-point, and vs the respective pretreatment baseline).

——

Post hoc analysis shows that the prototypic non-peptide CRF1 receptor antagonist NBI30775 (R121919) and Verucerfont are both significantly different from vehicle, CP-316?311, and pexacerfont (P<0.001 for all comparisons collapse across time-points); the latter three treatments in turn do not differ from each other. A differential effect of treatments over time is also shown by a significant treatment×time interaction (F[20,140]=6.4, P<0.001). Accordingly, detailed Post hocanalysis shows that both NBI30775 and Verucerfont inhibit ACTH release throughout the following 6?h of measurement (P<0.001 vs vehicle at each time-point, and vs the respective pretreatment baseline).

GSK561679 | NBI77860

GPCR/G Protein

CRF Receptor

CRF

Neurological Disease

Alcoholism; Post-traumatic stress disorders

885220-61-1

406.48

C22H26N6O2

>98% (HPLC)

DMSO:86.7 mg/mL (213.29 mM)

CCC(Nc1cc(C)nc2c(-c3ccc(OC)cc3C)c(C)nn12)c1nc(C)no1

(S)-3-(4-methoxy-2-methylphenyl)-25-dimethyl-N-(1-(3-methyl-124-oxadiazol-5-yl)propyl)pyrazolo[15-a]pyrimidin-7-amine

(-20℃)

With Ice Pack

≥ 2 years